Get the Stockscreener App
9.8864
0.35%
-0.0436
Capricor Therapeutics Inc stock is traded at $9.8864, with a volume of 727.00K.
It is down -0.35% in the last 24 hours and up +0.05% over the past month.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
See More
Previous Close:
$9.93
Open:
$9.69
24h Volume:
727.00K
Relative Volume:
0.34
Market Cap:
$634.88M
Revenue:
$27.10M
Net Income/Loss:
$-24.31M
P/E Ratio:
-11.91
EPS:
-0.83
Net Cash Flow:
$-33.33M
1W Performance:
+6.97%
1M Performance:
+0.05%
6M Performance:
-28.30%
1Y Performance:
+104.44%
1-Day Range:
$9.47
$10.02
1-Week Range:
$8.91
$11.58
52-Week Range:
$3.52
$23.40
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Name
Capricor Therapeutics Inc
Sector
Industry
Phone
(310) 358-3200
Address
8840 WILSHIRE BLVD, BEVERLY HILLS, CA
Compare CAPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
9.9006 | 634.88M | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.24 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
539.58 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.27 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
551.96 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-20-25 | Initiated | Roth Capital | Buy |
| Oct-21-24 | Initiated | Piper Sandler | Overweight |
| May-17-24 | Initiated | Oppenheimer | Outperform |
| Jan-05-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-26-22 | Initiated | Ladenburg Thalmann | Buy |
| Dec-26-18 | Downgrade | Maxim Group | Buy → Hold |
| Jan-26-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-15-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-17 | Resumed | Rodman & Renshaw | Buy |
| Jul-06-16 | Resumed | H.C. Wainwright | Buy |
| Jun-15-16 | Initiated | ROTH Capital | Buy |
View All
Capricor Therapeutics Inc Stock (CAPR) Latest News
US FDA’s Top Cell and Gene Therapy Regulators Forced Out - insights.citeline.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor - Bluefield Daily Telegraph
Capricor gets FDA's Orphan Drug status for muscle disorder therapy - MSN
Capricor Therapeutics Announces Orphan Drug Designation for - GlobeNewswire
Capricor Therapeutics (CAPR) Rating Reiterated by Roth Capital | CAPR Stock News - GuruFocus
Capricor Therapeutics (CAPR) Gains FDA Orphan Drug Status for Deramiocel - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc.CAPR - PR Newswire
Capricor Therapeutics' Deramiocel Wins FDA Orphan Drug Designation for Becker Muscular Dystrophy - MarketScreener
Capricor Therapeutics (CAPR) Receives Orphan Drug Designation for BMD Treatment | CAPR Stock News - GuruFocus
Capricor Scores Double Win: FDA Orphan Drug Status for Becker MD Plus DMD Approval Progress - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor ... - Eagle-Tribune
FDA Grants Orphan Status to Capricor's Becker Muscular Dystrophy Treatment (CAPR) | CAPR Stock News - GuruFocus
Capricor Therapeutics (CAPR) Shares Dip Seen as Buying Opportuni - GuruFocus
Capricor Therapeutics (CAPR) Sees Unusual Put Activity | CAPR St - GuruFocus
Capricor (CAPR) Shares Decline Amid FDA Advisory Panel Developments | CAPR Stock News - GuruFocus
Capricor Therapeutics (CAPR) Receives Buy Rating from HC Wainwri - GuruFocus
Capricor Therapeutics (CAPR) Receives Buy Rating from HC Wainwright & Co. | CAPR Stock News - GuruFocus
Capricor Therapeutics (CAPR) Shares Drop After FDA Withdraws Mee - GuruFocus
Capricor gets Form 483 from FDA; WuXi Biologics’ new China factory - Endpoints News
Capricor says FDA inspection brought Form 483 with several observations - Yahoo Finance
Capricor Therapeutics (CAPR) Manufacturing Facility Cleared by F - GuruFocus
Capricor Therapeutics (CAPR) Shares Decline Amid FDA Inspection Report - GuruFocus
Capricor Therapeutics (CAPR) Advances Deramiocel Approval Proces - GuruFocus
Capricor: A Hold Rating With Regulatory FDA Form Given For Deramiocel Advancement (CAPR) - Seeking Alpha
Capricor Therapeutics Announces Key Regulatory Updates for its D - GuruFocus
FDA Completes Inspection of Capricor Therapeutics Manufacturing Facility For Deramiocel Approval: Retail Sees ‘Unimaginable Potential’ - Asianet Newsable
Capricor Therapeutics (CAPR) Manufacturing Facility Cleared by FDA | CAPR Stock News - GuruFocus
Capricor Therapeutics' Duchenne Therapy Facility Inspection Completed by FDA - MarketScreener
Capricor falls after facility inspection related to deramiocel - Seeking Alpha
Capricor Therapeutics stock falls after FDA inspection of manufacturing facility - Investing.com Australia
Capricor Therapeutics stock falls after FDA inspection of manufacturing facility By Investing.com - Investing.com Nigeria
Capricor’s DMD therapy clears FDA pre-license inspection By Investing.com - Investing.com Canada
Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program - GlobeNewswire
Capricor's DMD Drug Hits 3 Major FDA Milestones: Advisory Committee Set for July 30 - Stock Titan
Cantor Fitzgerald Estimates CAPR FY2026 Earnings - Defense World
Behind the Scenes of Capricor Therapeutics's Latest Options Trends - Benzinga
(CAPR) Trading Signals - news.stocktradersdaily.com
Wellington Management Group LLP Purchases New Position in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Therapeutics Sees Unusually High Options Volume (NASDAQ:CAPR) - Defense World
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Capricor Therapeutics, Inc.CAPR - FinancialContent
Capricor Therapeutics (CAPR) Sees Borrow Rate Surge | CAPR Stock News - GuruFocus
Millennium Management LLC Acquires 12,285 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
BNP Paribas Financial Markets Reduces Stake in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Two Sigma Investments LP Has $1.64 Million Stake in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Bank of America Corp DE Purchases 154,127 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeutics, Inc. (CAPR) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Capricor Therapeutics, Inc. (CAPR) And Encourages Shareholders to Connect - ACCESS Newswire
Capricor Therapeutics Inc (NASDAQ:CAPR) Shares Bought by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
Deutsche Bank AG Takes Position in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Capricor Therapeutics, Inc. (CAPR) And Encourages Shareholders to Reach Out - ACCESS Newswire
Capricor Therapeutics Inc Stock (CAPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Capricor Therapeutics Inc Stock (CAPR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Mar 03 '25 |
Option Exercise |
1.39 |
2,500 |
3,475 |
8,223 |
| Litvack Frank | Director |
Mar 03 '25 |
Option Exercise |
1.39 |
25,000 |
34,750 |
132,382 |
| DUNBAR GEORGE W JR | Director |
Mar 03 '25 |
Option Exercise |
1.39 |
750 |
1,042 |
11,306 |
| COLLIER EARL M JR | Director |
Feb 27 '25 |
Option Exercise |
1.39 |
750 |
1,042 |
57,606 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Dec 13 '24 |
Option Exercise |
1.39 |
8,000 |
11,120 |
28,047 |
| Litvack Frank | Director |
Dec 03 '24 |
Option Exercise |
1.10 |
20,391 |
22,430 |
46,278 |
| Nippon Shinyaku Co Ltd | 10% Owner |
Sep 20 '24 |
Buy |
5.36 |
2,798,507 |
14,999,998 |
7,090,351 |
| Musket David B | Director |
Aug 07 '24 |
Option Exercise |
1.39 |
34,000 |
47,260 |
81,692 |
0.80%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):